Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.66 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CCR1 | P32246 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13902182 | 0.90 | SMN1; SMN2 (0.68) | SMN1; SMN2NPY5RROCK1KDM4EMAPT | |
| SCHEMBL13902185 | 0.88 | SMN1; SMN2 (0.69) | SMN1; SMN2NPY5RROCK1KDM4EGAA | |
| SCHEMBL8003176 | 0.83 | SMN1; SMN2 (0.74) | SMN1; SMN2NPY5RROCK1KDM4EMAPT | |
| SCHEMBL13754395 | 0.81 | SMN1; SMN2 (0.69) | SMN1; SMN2NPY5RROCK1KDM4EMAPT | |
| SCHEMBL4018661 | 0.81 | POLB (0.70) | SMN1; SMN2ROCK1KDM4EGAAMAPT | |
| SCHEMBL17324760 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2ROCK1KDM4EMAPTNPC1 | |
| SCHEMBL2079393 | 0.78 | SMN1; SMN2 (0.62) | SMN1; SMN2NPY5RROCK1KDM4EMAPT | |
| SCHEMBL17321499 | 0.78 | SMN1; SMN2 (0.63) | SMN1; SMN2ROCK1KDM4EGAAMAPT | |
| SCHEMBL13902183 | 0.76 | JAK3 (0.71) | SMN1; SMN2ROCK1KDM4EMAPTNPC1 | |
| SCHEMBL17311616 | 0.75 | ROCK1 (1.00) | SMN1; SMN2ROCK1KDM4EMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | SMN1; SMN2 3501/4885NPY5R 4771/4885ROCK1 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.